Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease

Authors Bertens LCM, Reitsma JB, Moons KGM, van Mourik Y, Lammers JWJ, Broekhuizen BDL, Hoes AW, Rutten FH

Received 7 June 2013

Accepted for publication 24 July 2013

Published 10 October 2013 Volume 2013:8 Pages 493—499

DOI https://doi.org/10.2147/COPD.S49609

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Loes CM Bertens,1 Johannes B Reitsma,1 Karel GM Moons,1 Yvonne van Mourik,1 Jan Willem J Lammers,2 Berna DL Broekhuizen,1 Arno W Hoes,1 Frans H Rutten1

1Julius Center for Health Sciences and Primary Care, 2Department of Pulmonology, Heart-Lung Center, University Medical Center Utrecht, Utrecht, the Netherlands

Purpose: Prediction models for exacerbations in patients with chronic obstructive pulmonary disease (COPD) are scarce. Our aim was to develop and validate a new model to predict exacerbations in patients with COPD.
Patients and methods: The derivation cohort consisted of patients aged 65 years or over, with a COPD diagnosis, who were followed up over 24 months. The external validation cohort consisted of another cohort of COPD patients, aged 50 years or over. Exacerbations of COPD were defined as symptomatic deterioration requiring pulsed oral steroid use or hospitalization. Logistic regression analysis including backward selection and shrinkage were used to develop the final model and to adjust for overfitting. The adjusted regression coefficients were applied in the validation cohort to assess calibration of the predictions and calculate changes in discrimination applying C-statistics.
Results: The derivation and validation cohort consisted of 240 and 793 patients with COPD, of whom 29% and 28%, respectively, experienced an exacerbation during follow-up. The final model included four easily assessable variables: exacerbations in the previous year, pack years of smoking, level of obstruction, and history of vascular disease, with a C-statistic of 0.75 (95% confidence interval [CI]: 0.69–0.82). Predictions were well calibrated in the validation cohort, with a small loss in discrimination potential (C-statistic 0.66 [95% CI 0.61–0.71]).
Conclusion: Our newly developed prediction model can help clinicians to predict the risk of future exacerbations in individual patients with COPD, including those with mild disease.

Keywords: exacerbation of COPD, risk prediction, external validation, vascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Chronic obstructive pulmonary disease exacerbation frequency and severity

Stafyla E, Kerenidi T, Gourgoulianis KI

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:533-535

Published Date: 6 November 2013

Changes in the airway lumen and surrounding parenchyma in chronic obstructive pulmonary disease

Kurashima K, Hoshi T, Takaku Y, Kanauchi T, Nakamoto K, Ueda M, Takayanagi N, Colby TV, Sugita Y, Kawabata Y

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:523-532

Published Date: 30 October 2013

COPD management: role of symptom assessment in routine clinical practice

van der Molen T, Miravitlles M, Kocks JWH

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:461-471

Published Date: 14 October 2013

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:425-432

Published Date: 18 September 2013

Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease

Yoon HI, Lee CH, Kim DK, Park GM, Lee SM, Yim JJ, Kim JY, Lee JH, Lee CT, Chung HS, Kim YW, Han SK, Yoo CG

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:329-334

Published Date: 10 July 2013

The association between COPD and heart failure risk: a review

de Miguel Díez J, Chancafe Morgan J, Jiménez García R

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:305-312

Published Date: 28 June 2013

Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease

Kocks JWH, van den Berg JWK, Kerstjens HAM, Uil SM, Vonk JM, de Jong YP, Tsiligianni IG, van der Molen T

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:273-286

Published Date: 6 June 2013